Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

FDA approves Pfizer's Xeljanz for rheumatoid arthritis

Nov. 8, 2012

New JNK1 inhibitors revealed by Roche

Nov. 7, 2012

Lilly Japan and Chugai to terminate Evista comarketing agreement in Japan

Nov. 6, 2012

Roche presents new SYK kinase inhibitors

Nov. 2, 2012

Teijin Pharma to begin phase I/II trial of KTP-001

Oct. 30, 2012

Investigator-sponsored trial of Cytori's cell therapy for scleroderma cleared in France

Oct. 25, 2012

Team at Harvard College patents new TNF-alpha production inhibitors

Oct. 17, 2012

FDA approves expanded indication for Actemra

Oct. 16, 2012

New CCR2 receptor antagonists presented by Merck & Co.

Oct. 16, 2012

Ablynx reports promising interim results from phase I/II ALX-0061 study

Oct. 5, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 15, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Rethinking anorexia: A disorder of mind and metabolism
BioWorld Science
Anorexia nervosa (AN) is a complex and severe eating disorder that has long been considered a psychiatric condition driven by distorted body image and maladaptive...